Interleukin-17A Antagonist
An Established Pharmacologic Class (EPC) in the FDA NDC Directory: the class FDA records for a product in its PHARM_CLASSES field.
In the NADAC file of 2026-10-14
8 products in the NADAC file of 2026-10-14 have an NDC that FDA lists in this class, covering 2 nonproprietary names as FDA writes them. 3 of them have a Medicare figure on OpenBill.
Being in one class means FDA describes the drugs’ pharmacology the same way. It does not mean one can replace another; that is a question for your prescriber.
Prices per unit: CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · as of 2026-10-14 · retrieved 2026-10-17. Classes: FDA NDC Directory · ndctext.zip · as of 2026-10-16.
The products, with what pharmacies pay per unit
- COSENTYX (150 MG/ML) 300 MG DOSE-2 SYRINGES
- COSENTYX 150 MG/ML SYRINGE
- COSENTYX SENSOREADY 150 MG/ML PEN
- COSENTYX SENSOREADY 300 MG DOSE/2 PENS (150 MG/PEN)
- COSENTYX UNOREADY 300 MG/2 ML PEN (1 PEN)
- TALTZ 80 MG/ML AUTOINJECTOR
- TALTZ 80 MG/ML AUTOINJECTOR (2-PACK)
- TALTZ 80 MG/ML AUTOINJECTOR (3-PACK)
How to read these prices
OpenBill holds every page to these five rules, written by the project’s owner and quoted word for word:
- A price is a range to expect, never a quote.
- Medicare's price is not your price. Say so on every screen that shows it.
- State which dataset and which effective date produced every figure.
- If a source is stale or a file is empty, show that rather than a zero.
- Disclaimer footer: not medical advice, no warranty, other people's data can be wrong.